Equities analysts expect that Evoke Pharma, Inc. (NASDAQ:EVOK) will report ($0.20) earnings per share for the current quarter, according to Zacks. Zero analysts have made estimates for Evoke Pharma’s earnings, with the highest EPS estimate coming in at ($0.16) and the lowest estimate coming in at ($0.26). Evoke Pharma posted earnings of ($0.18) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 11.1%. The firm is expected to announce its next quarterly earnings report on Wednesday, March 21st.
On average, analysts expect that Evoke Pharma will report full year earnings of ($0.79) per share for the current year, with EPS estimates ranging from ($0.83) to ($0.75). For the next fiscal year, analysts expect that the business will post earnings of $0.10 per share, with EPS estimates ranging from ($0.52) to $1.16. Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that cover Evoke Pharma.
Evoke Pharma (NASDAQ:EVOK) last issued its earnings results on Tuesday, November 14th. The specialty pharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.13). During the same quarter last year, the business posted ($0.29) EPS.
Institutional investors have recently made changes to their positions in the business. State Treasurer State of Michigan raised its position in Evoke Pharma by 37.0% during the 2nd quarter. State Treasurer State of Michigan now owns 400,000 shares of the specialty pharmaceutical company’s stock worth $1,024,000 after buying an additional 108,034 shares during the last quarter. Vanguard Group Inc. raised its position in Evoke Pharma by 15.1% during the 2nd quarter. Vanguard Group Inc. now owns 523,650 shares of the specialty pharmaceutical company’s stock worth $1,341,000 after buying an additional 68,544 shares during the last quarter. Finally, Sphera Funds Management LTD. raised its position in Evoke Pharma by 14.2% during the 3rd quarter. Sphera Funds Management LTD. now owns 571,022 shares of the specialty pharmaceutical company’s stock worth $1,907,000 after buying an additional 71,022 shares during the last quarter. Institutional investors own 13.33% of the company’s stock.
Shares of Evoke Pharma (NASDAQ EVOK) traded up $0.16 during trading on Monday, hitting $2.79. 86,900 shares of the stock traded hands, compared to its average volume of 424,781. Evoke Pharma has a fifty-two week low of $1.42 and a fifty-two week high of $4.55.
About Evoke Pharma
Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Evoke Pharma Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Evoke Pharma Inc. and related companies.